|1.||Crohn Disease (Crohn's Disease)
|3.||Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
|1.||Sandborn, William J: 78 articles (01/2016 - 04/2002)|
|2.||Rutgeerts, Paul: 74 articles (12/2015 - 02/2002)|
|3.||Shen, Bo: 73 articles (01/2016 - 08/2004)|
|4.||Van Assche, Gert: 44 articles (12/2015 - 10/2002)|
|5.||Hibi, Toshifumi: 39 articles (01/2015 - 01/2002)|
|6.||Matsumoto, Takayuki: 38 articles (10/2015 - 02/2002)|
|7.||Remzi, Feza H: 37 articles (02/2015 - 10/2002)|
|8.||Vermeire, Séverine: 36 articles (12/2015 - 10/2003)|
|9.||Lichtenstein, Gary R: 33 articles (09/2015 - 10/2002)|
|10.||Danese, Silvio: 32 articles (12/2015 - 04/2005)|
|1.||Mesalamine (Mesalazine)FDA LinkGeneric
01/01/2007 - "* In a well designed phase III trial in patients with active, mild to moderate ulcerative colitis (n = 262), significantly (p < 0.01) more MMX mesalazine 2.4 (34%) or 4.8 g/day (29%) recipients than placebo recipients (13%) achieved clinical and endoscopic remission after 8 weeks of treatment.* In a second phase III trial (n = 341), clinical and endoscopic remission rates with MMX mesalazine 2.4 (40.5%) and 4.8 g/day (41.2%) were significantly (p < 0.01) greater than with placebo (22.1%) after 8 weeks, while the remission rate with non-MMX delayed-release mesalazine (Asacol) [32.6%] did not differ from placebo.* Overall, MMX mesalazine was generally well tolerated in controlled clinical trials, with a similar incidence of treatment-emergent adverse events in placebo (66%) and MMX mesalazine (56%) recipients in a pooled analysis; most adverse events were of mild or moderate severity. "
02/01/2011 - "Mesalazine 3.0 g once daily was the most effective dose for maintenance of remission in ulcerative colitis of the three regimens assessed, with no penalty in terms of safety."
08/01/2010 - "Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine."
09/21/2009 - "5-Aminosalicylic acid (5-ASA) compounds are a highly effective treatment for ulcerative colitis (UC). "
07/01/2007 - "5-Aminosalicylate (5-ASA; mesalamine) is the current first-line treatment for mild to moderate ulcerative colitis, a chronic inflammatory condition that most commonly affects the distal part of the colon. "
|2.||infliximab (Remicade)FDA Link
08/01/2013 - "Rescue therapy with infliximab (IFX) has been proven effective in a steroid-refractory attack of ulcerative colitis (UC). "
09/20/2009 - "Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. "
06/01/2007 - "Infliximab also has proven to be efficacious in patients with ulcerative colitis (UC) and has increased rates of steroid-free remission. "
06/01/2006 - "[Infliximab in active ulcerative colitis -- proven efficacy as induction and maintenance treatment]."
08/01/2001 - "Infliximab appears to be a potent agent for inducing remission in refractory patients with ulcerative colitis."
|3.||Sulfasalazine (Azulfidine)FDA LinkGeneric
12/01/1985 - "Sulfasalazine is of proven efficacy as maintenance therapy in ulcerative colitis. "
09/01/1990 - "Since the development of sulfasalazine about a half century ago, the prognosis for patients with ulcerative colitis has improved significantly. "
04/01/1985 - "In the case of sulphasalazine, adult slow acetylators require a lower daily dose of the drug than fast acetylators in order to maintain ulcerative colitis in remission without significant side effects. "
08/01/1985 - "The disparity of the therapeutic efficacy and effects on NK activity of sulphasalazine and its derivatives in vitro may suggest that NK activity is not a major pathogenic mechanism in ulcerative colitis. "
05/01/1983 - "Sulfasalazine is of major benefit in preventing relapses in patients with ulcerative colitis in remission. "
|4.||Cyclosporine (Ciclosporin)FDA LinkGeneric
03/01/2010 - "Cyclosporin A (CSA), an immunosuppressive agent, is highly efficacious in patients with refractory ulcerative colitis (UC). "
10/01/2003 - "Cyclosporine A is highly effective in severe attacks of ulcerative colitis (UC) but is associated with important adverse effects that are mainly dose dependent. "
01/01/2012 - "Ciclosporin has proven to be effective in patients with corticosteroid-refractory ulcerative colitis (UC). "
11/01/2008 - "Cyclosporine A (CsA) has been found to be the first successful therapy used in the recovery of patients with steroid-refractory ulcerative colitis (UC). "
09/04/1998 - "Our data confirm the efficacy of intravenous cyclosporine as a rapid acting drug for severe ulcerative colitis. "
|5.||Azathioprine (Imuran)FDA LinkGeneric
01/01/2002 - "The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis."
07/04/1992 - "Azathioprine maintenance treatment in ulcerative colitis is beneficial for at least two years if patients have achieved remission while taking the drug. "
01/01/2012 - "Azathioprine therapy appears to be more effective than placebo for maintenance of remission in ulcerative colitis. "
05/22/2004 - "To know whether the therapeutic protocol applied in the case of severe acute ulcerative colitis (UC) associating ciclosporine and azathioprine was also effective in the case of moderate chronic active ulcerative colitis (UC). "
10/01/2002 - "Azathioprine is effective in patients with steroid-dependent or steroid-resistant ulcerative colitis. "
|6.||Adrenal Cortex Hormones (Corticosteroids)IBA
09/01/2008 - "The introduction of corticosteroids in the 1950s dramatically improved the prognosis of patients with severe ulcerative colitis. "
11/01/2014 - "In patients with more extensive ulcerative colitis, treatment occurs in a step-up fashion (5-ASA, corticosteroids, thiopurines, anti-TNF-α agents), a strategy which has proven effective. "
09/28/2008 - "Corticosteroids are still the first-line treatment for active ulcerative colitis more than 50 years after the publication of trials assessing their beneficial effect, with about a 50% remission rate in cases of severe disease. "
06/01/2006 - "Centrifugal leukocytapheresis without corticosteroid treatment can induce remission in patients with active ulcerative colitis, and might be particularly beneficial for patients in whom adverse effects preclude the use of corticosteroids."
05/01/1998 - "Therapy with high-dose corticosteroids led to healing of the skin and upper eyelid lesions and induced remission of ulcerative colitis."
09/28/2008 - "Although systemic steroids are highly efficacious in ulcerative colitis (UC), failure to respond to steroids still poses an important challenge to the surgeon and physician alike. "
11/01/1999 - "Despite its intermittent course of activity and remission, the good response to salazopyridine and steroids makes the long-term prognosis of ulcerative colitis favorable. "
06/01/2010 - "Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year."
07/01/1995 - "Sixty percent (18/30) of severe ulcerative colitis were in remission after mean duration of 9.2 days (range 2-20 days) of intensive intravenous therapy without major side effects of steroids. "
11/01/2012 - "Intravenous steroids are considered the mainstay of treatment in patients with severe ulcerative colitis. "
|8.||adalimumab (Humira)FDA Link
01/01/2013 - "Adalimumab treatment was associated with a positive benefit/risk balance in the overall population of patients with moderately-to-severely active ulcerative colitis in ULTRA 2; early response was predictive of a positive outcome at 1 year (NCT00408629)."
12/01/2011 - "More recently, data has been published demonstrating the efficacy of adalimumab in patients with ulcerative colitis."
01/01/2014 - "Adalimumab is effective for induction and maintenance of remission in patients with moderate to severe ulcerative colitis (UC). "
09/01/2013 - "In this large "real-life" experience adalimumab appears effective in patients with otherwise medically refractory ulcerative colitis. "
01/01/2013 - "Taken together, the current evidence indicates that adalimumab is effective for the treatment of patients with different types of ulcerative colitis, including biologically naïve and difficult-to-treat patients."
|9.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
08/01/2007 - "Recent randomized controlled trials have confirmed that biologic anti-TNFalpha therapy is effective in ulcerative colitis. "
01/01/2014 - "Efficacy of tumor necrosis factor alpha (TNF-α) blockers for treatment of ulcerative colitis that is unresponsive to conventional therapy is unclear due to recent studies yielding conflicting results. "
05/01/1997 - "These studies indicate the efficacy of selective antibody therapy to TNF alpha for the treatment of ulcerative colitis in a primate and suggest that similar therapy in human could be of value."
06/09/2008 - "The treatment of ulcerative colitis has improved since the appearance of Tumor Necrosis Factor (TNF)-alpha inhibitors. "
10/01/2002 - "Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis."
|10.||6-Mercaptopurine (Mercaptopurine)FDA LinkGeneric
03/01/2004 - "6-mercaptopurine has proven to be effective in the treatment and maintenance of remission of ulcerative colitis (UC). "
06/01/1990 - "The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis."
05/01/2011 - "The paper under evaluation brings new insight into the molecular events underlying EMN development in a patient receiving 6-mercaptopurine immunosuppressive therapy for ulcerative colitis. "
08/01/2010 - "6-Mercaptopurine (6-MP) is an effective maintenance medication in patients with ulcerative colitis (UC), but toxic effects like myelosuppression limit its clinical benefit. "
03/01/2008 - "We report a case of a 50-year-old woman with refractory ulcerative colitis chronically treated with 6-mercaptopurine that developed severe squamous dysplasia of the rectum. "
04/20/1993 - "5-ASA enemas are very effective in the treatment of distal ulcerative colitis. "
06/01/1986 - "We conclude that in patients with distal ulcerative colitis unresponsive to standard therapy, treatment with 5-ASA enemas results in significant short-term clinical and sigmoidoscopic improvement in a majority of cases. "
09/01/2005 - "To explore the therapeutic efficacy of patients with ulcerative colitis (UC) treated by retention enema and per-colonoscopic spraying of Zhikang Compound Liquid (ZKCL). "
01/01/1998 - "Are short-chain fatty acid enemas effective for left-sided ulcerative colitis?"
06/01/1995 - "Some evidence indicates that short-chain fatty acid (SCFA) enemas are effective in the treatment of distal ulcerative colitis. "
09/01/2011 - "A significant proportion of patients with ulcerative colitis will still have to undergo colectomy and overall half of the patients do not achieve sustained remission, leading to impairment of physical and mental health, social life, employment issues and sexual activity. "
09/01/2006 - "Our findings may help to predict patients with ulcerative colitis who have a high risk for colectomy."
10/01/1995 - "This study suggests that AI will be useful in evaluation of response to medical therapy and prediction of remission and colectomy in patients with moderately active ulcerative colitis."
08/01/2014 - "Conversely, smoking appears protective against ulcerative colitis and smokers are less likely to require colectomy. "
01/01/2014 - "TNF-α blockers are effective and safe therapies for the induction and maintenance of long-term remission and prevention of treatment by colectomy for patients with refractory ulcerative colitis where conventional treatment was previously ineffective. "
|3.||Blood Component Removal (Apheresis)
12/01/2009 - "An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment."
12/07/2014 - "Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease."
11/28/2005 - "Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis."
02/01/2009 - "Leukocytapheresis is effective for ulcerative colitis (UC), and both peripheral leukocyte and platelet counts decrease during apheresis. "
01/01/2008 - "Recently, granulocyte and monocyte adsorption apheresis (GMA) has been shown to be effective for active ulcerative colitis (UC). "
03/01/2013 - "Although accumulating studies in Japan show that cytapheresis (CAP) therapy is safe and effective for the induction of remission of moderate or severe ulcerative colitis (UC), the long-term prognosis of UC patients treated with CAP is unknown. "
11/01/2011 - "Furthermore, this review also examines in-depth the probiotic clinical trials published between 2007 and December 2010, providing new insights into the role of probiotics for inducing and maintaining remission of IBD, and highlighting some of the breakthroughs, especially regarding induction of remission for ulcerative colitis."
01/01/2007 - "This review evaluates the efficacy of fish oil for induction of remission in ulcerative colitis using all available randomised controlled trials. "
01/01/2009 - "Randomized controlled trials comparing MLN-02 to placebo or a control therapy for the induction of remission in ulcerative colitis were included. "
01/01/2008 - "This trial suggests a potential benefit over placebo for both achieving clinical response and induction of remission in patients with active ulcerative colitis without apparent toxicity."
10/01/2010 - "There are clearly significant adverse affects on health-related quality of life in children with ulcerative colitis that dramatically improved following restorative proctocolectomy."
06/01/2001 - "Restorative proctocolectomy has dramatically improved the treatment of familial polyposis and ulcerative colitis with rectal involvement. "
01/01/2014 - "Restorative proctocolectomy with ileal pouch-anal anastomosis is safe and effective in selected very elderly patients suffering from ulcerative colitis."
11/14/2007 - "While restorative proctocolectomy with ileal pouch-anal anastomosis has significantly improved the quality of life in patients with underlying ulcerative colitis who require surgery, complications can occur. "
07/01/1993 - "Restorative proctocolectomy is a major advance in the management of ulcerative colitis."